Literature DB >> 16078843

A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.

Mathew P Leese1, Hatem A M Hejaz, Mary F Mahon, Simon P Newman, Atul Purohit, Michael J Reed, Barry V L Potter.   

Abstract

Efficient and flexible syntheses of 2-substituted estrone, estradiol and their 3-O-sulfamate (EMATE) derivatives have been developed using directed ortho-lithiation methodology. 2-Substituted EMATEs display a similar antiproliferative activity profile to the corresponding estradiols against a range of human cancer cell lines. 2-Methoxy (3, 4), 2-methylsulfanyl (20, 21) and 2-ethyl EMATEs (32, 33) proved the most active compounds with 2-ethylestradiol-3-O-sulfamate (33), displaying a mean activity over the NCI 55 cell line panel 80-fold greater than the established anticancer agent 2-methoxyestradiol (2). 2-Ethylestradiol-3-O-sulfamate (33) was also an effective inhibitor of angiogenesis using three in vitro markers, and various 2-substituted EMATEs also proved to be inhibitors of steroid sulfatase (STS), a therapeutic target for the treatment of hormone-dependent breast cancer. The potential of this novel class of multimechanism anticancer agents was confirmed in vivo with good activity observed in the NCI hollow fiber assay and in a MDA-MB-435 xenograft mouse model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078843     DOI: 10.1021/jm050066a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors.

Authors:  Mathew P Leese; Fabrice L Jourdan; Meriel R Major; Wolfgang Dohle; Ernest Hamel; Eric Ferrandis; Ann Fiore; Philip G Kasprzyk; Barry V L Potter
Journal:  ChemMedChem       Date:  2013-10-09       Impact factor: 3.466

2.  Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  J Med Chem       Date:  2015-06-12       Impact factor: 7.446

3.  The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Authors:  Chloe Stengel; Simon P Newman; Mathew P Leese; Mark P Thomas; Barry V L Potter; Michael J Reed; Atul Purohit; Paul A Foster
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

4.  In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.

Authors:  X X Stander; B A Stander; A M Joubert
Journal:  Cell Prolif       Date:  2011-10-13       Impact factor: 6.831

5.  Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Authors:  Wolfgang Dohle; Mathew P Leese; Fabrice L Jourdan; Christopher J Chapman; Ernest Hamel; Eric Ferrandis; Barry V L Potter
Journal:  ChemMedChem       Date:  2014-05-12       Impact factor: 3.466

6.  Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.

Authors:  C Stengel; S P Newman; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

Review 7.  Use of the in vivo hollow fiber assay in natural products anticancer drug discovery.

Authors:  Qiuwen Mi; John M Pezzuto; Norman R Farnsworth; Mansukh C Wani; A Douglas Kinghorn; Steven M Swanson
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

8.  Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors.

Authors:  Mathew P Leese; Fabrice Jourdan; Wolfgang Dohle; Meriel R Kimberley; Mark P Thomas; Ruoli Bai; Ernest Hamel; Eric Ferrandis; Barry V L Potter
Journal:  ACS Med Chem Lett       Date:  2011-10-31       Impact factor: 4.345

9.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors:  J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

Authors:  M F C Parsons; P A Foster; S K Chander; R Jhalli; S P Newman; M P Leese; B V L Potter; A Purohit; M J Reed
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.